Portfolio Companies & Business Units
Roslin Technologies’ value is created from the successful commercialisation of technologies, starting from small scale seeding projects through to the creation or acquisition of large scale connected and complimentary Business Units or Portfolio Companies. The goal of Roslin Technologies is to build high value in these Ag-Tech Ventures that together deliver attractive returns but also may represent spin off opportunities in future. Below are the entities we have built since our inception in 2016.
LEO WEIN, CEO
Leo Wein (CEO Protenga) has degrees in both Science and Business from Amsterdam University College and the Free University of Amsterdam. He has a background in product development and software engineering. Leo brings a passionate entrepreneurial approach to all his ventures and is the founder of Protenga.
Protenga harnesses the natural power of the Black Soldier Fly (Hermetia illucens) to extract nutrients and decompose organic side-streams in science-based, engineered systems. The company produces and distributes insect-based nutrition for aquaculture, premium livestock, pet food and plants. Core products include: Hermet Protein; Hermet Oil; ReFood Fertilizer.
DR SIMON WHEELER, CEO
Simon Wheeler (CEO Vetsina) is a European Specialist in Veterinary Neurology and a Fellow of the Royal College of Veterinary Surgeons. He has a wealth of experience in the pharmaceutical industry covering technical, commercial and innovation roles.
The revolutionary chemical-based system allows detection of nucleic acid sequences & single nucleotide polymorphism to directly detect small miRNA’s in a rapid, accurate & cost effective PCR-free detection system without the multiple steps required by current methods.
Vetsina develops, and offers, the veterinary and animal health industries, innovative nucleic acid testing and molecular assay
solutions, with particular emphasis on miRNA detection and quantification.
Dr Alfredo Lepori, Geneticist
ARK provides phenotyping and genomic services to leading animal biotechnology companies by applying translational technologies through its breeding programmes to improve productivity, sustainability and animal health. At ARK’s core is a physical platform designed to monitor and develop breeding programmes to enhance performance of multi-species under commercial conditions.
ARK establishes and operates a genetic nucleus for each target species including insect, prawns and livestock in which extensive phenotypic data is collected as the animals breed, develops and grows. Simultaneously, sensors collect environmental data in which the animals are growing and samples are collected for genomic analysis. All data is analyzed to assess variances and correlations. The information then used to adapt the breeding programmes through advanced genetic evaluation systems. The information, discoveries, data and high performing breeding animals are made available to partners and third party operations globally to seed and enhance their breeding operations.
ARK services are offered to major breeding companies, researchers and commercial operations for line development or as an integral extension of their R&D programmes.
Dr Joe Mee, Chief Scientific Officer
The company has also developed commercially innovative techniques to extract and biobank primordial cells from avian species for breeding and conservation industries in its “Frozen Aviary” unit. It also biobanks other tissues for clients to preserve, undertake genomic analysis or create specialised cell-lines.